Abstract
Many studies have shown the presence of minimal residual disease (MRD) following therapy for childhood acute lymphoblastic leukemia (ALL) to be an important prognostic marker. We have also shown a significant relationship between survival outcomes in patients enrolled in the previous ALL 911 study and molecular MRD levels 5 weeks (time point 1, TP1) and 12 weeks (TP2) following the initiation of chemotherapy (
Leukaemia and Lymphoma
2002
; 43
: 1001
Leukaemia and Lymphoma
2002
; 43
: 1001
[Acknowledgment: This study was partly supported by grants from the Children’s Cancer Association of Japan (CCAJ)].
Disclosures: No relevant conflicts of interest to declare.
Author notes
Corresponding author
2008, The American Society of Hematology
2008